Peptides Are About to Get Regulated. That's the Best News in This Whole Category.
The FDA’s own scientists said no to all seven. The panel overruled them anyway. Here’s what that actually means, and what it doesn’t.
I get asked this question more than any other. So let’s actually answer it.
Housekeeping items first: I moved The Longevity Weekly news agent off Substack. If you enjoyed receiving the weekly news recap, please respond to this email to be added!
First, the news, and it’s not the news you think. Last week, the FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and DSIP. Six passed. BPC-157, KPV, and TB-500 each cleared 8-6. The panel is recommending they move toward the 503A compoundable list, the roster pharmacies can legally prepare against a prescription. Toward access, not away from it.
Interestingly, the FDA’s own career scientists recommended against all seven beforehand. The panel voted yes anyway. Eight of the panel’s voting seats were newly filled on June 29, 2026, weeks before the vote, and most of the new appointees have some financial ties to businesses that sell or administer peptides :)
None of this makes BPC-157 legal today, it still needs months of rulemaking, but it tells you exactly where this industry sits: politically ascendant, scientifically thin, impossible to ignore.
And to clarify where I stand - I personally am optimistic for peptides as compounds (and new business category!), and cautiously optimistic as it relates to my own body.
The good part of this story: quality control
A path to legal compounding means licensed pharmacies, tested batches, known dosing, replacing a supply chain that’s currently research-use-only vendors with no obligation to be consistent. That’s a real win, independent of whether any of these six peptides turn out to work as advertised. I’d rather see BPC-157 boring and regulated than exciting and unverifiable. The marketing hype around peptides is its own separate problem, and worth a piece on its own, but it’s not the one regulation actually fixes. Quality is.
So. Should you take one.
I haven’t found my answer either, and I’ve tried. Disclosure: I’m not on any peptides right now. I tried BPC-157, KPV, and SS-31 for under two months, hoping to fix a gut issue that didn’t get fixed. That doesn’t mean they don’t work. I tried to skip a step of actual healing before reaching for them.
Dr Mark Hyman recently told me that going from doing nothing straight to a peptide is skipping the workout and drinking the protein shake anyway. And I couldn’t find a better analogy since.
Peptides can do what people say they do. Only if you’re still doing the boring part first: sleep, training, food, stress. The peptide amplifies the fundamentals. It doesn’t replace them.
Three risk profiles, not two
“Peptides” gets treated like one category. It’s at least three.
GLP-1s sit in their own bucket, and it’s not close. Real Phase 3 programs, enormous literature. Retatrutide just posted the biggest weight-loss numbers this drug class has produced: roughly 28-30% body weight loss in trial. I’d bet on being on some version of a GLP-1 at some point in my life. But once these go oral, and that’s coming, they stop being a fringe intervention and become a normal maintenance drug.
The repair-and-inflammation peptides, the ones just in front of the FDA, BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, work through mechanisms like angiogenesis, mitochondrial signaling, and anti-inflammatory pathways. Human data is thin to nonexistent for most of them. Not dangerous by mechanism, just unproven, and that doesn’t mean they don’t work.
Worth being precise here: none of these six touch the growth hormone axis. BPC-157 works through VEGFR2 and angiogenesis, KPV is an anti-inflammatory alpha-MSH fragment, TB-500 acts on cell migration, MOTS-c is mitochondrial, Semax and Epitalon are nootropic and pineal-pathway compounds. That distinction matters for what comes next.
The growth hormone secretagogues, sermorelin, ipamorelin, CJC-1295, tesamorelin, are a different animal entirely, and this is where I’d actually slow down. I asked James Peyer, Phd, who runs Cambrian Bio and advises here (he’s building small-molecule longevity drugs, which makes him structurally skeptical), what’s happening mechanistically with this specific bucket. His read: growth hormone stimulation has a longevity problem baked in.
The mouse data behind Peyer’s warning
Every long-lived genetic mouse model we have shares one trait: low growth hormone. Ames dwarf mice live roughly 50% longer than normal littermates. Give them GH injections early in life and the longevity advantage disappears, permanently. More growth hormone, more IGF-1, more growth signaling, and growth signaling runs opposite to longevity signaling in the strongest lifespan models we have.
Peyer’s framing: you’re burning the candle twice as fast. You feel better, GH does make you feel better, but the mouse data says you may be trading rate of living for length of living. That’s a real trade to be making without knowing you’re making it.
Caveat, held loosely: this is mouse biology, not a proven human outcome on a sermorelin cycle. It’s a strong, replicated signal, not a verdict, and it applies specifically to the GH-secretagogue bucket above, not to BPC-157 or the others just cleared by the panel.
The other 40% of the peptide market, Peyer’s number, simply has no data either way. Not evidence of harm. No data. We’re running the world’s largest uncontrolled experiment and calling the results a category.
The one-liner I find hilarious
Dr. Jack Kreindler, who runs WellFounded.health, defined “peptide” as “a liquid that makes you feel more or less perky” depending on which way the marketing wind is blowing. His real point: hype is a separate problem from the molecule itself, and the industry has every incentive to blur the two.
Who profits, and why this fight is bigger than health
Lilly’s Zepbound and Mounjaro alone did $36.5 billion in 2025, more than half the company’s revenue. Analysts expect the combined GLP-1 category to clear $90 billion within a decade.
One theory circulating in DC: pharma would rather see off-label peptides restricted, since every compounded peptide is a patient not on a branded, patent-protected drug. I can’t verify this as coordinated strategy versus incentive alignment, treat it as a live hypothesis.
The actual businesses being built here, Superpower, System Labs, Protocol, and a growing list hitting my inbox weekly. Many of them are exciting with amazing founders behind them! The regulatory outcome decides whether this is a $500 million category or a $50 billion one.
If you’re going to do it
Get your IGF-1 checked regularly if you’re on anything in the growth-hormone-secretagogue bucket specifically. Standard blood test. If it climbs outside range, that’s your signal to get off, not push through.
Cycle on and off. Don’t run these continuously like a daily vitamin.
So, should you take a peptide
Firstly, I am not a doctor nor is any of this anything else than my personal opinion!
But IMO right now it depends entirely on which bucket you’re in, why, and whether you’ve done the boring stuff first. The category that’s actually transformative, GLP-1s, isn’t the one generating the loudest noise. The bucket generating the noise, and now getting a legal pathway, is running on thin human data but at least a clean mechanism. The bucket that gives me a pause is the one selling growth hormone, quietly, with the best mouse data in the field working against it.
As always, the real fix isn’t a better peptide. It’s connecting the ones we have to your own blood work, dosed to your body instead of a standard protocol. Nobody’s built that yet (though looks like RonanRX might be attempting).
Until then: know which bucket you’re in before you buy anything.
If this gave you something to think about, pass it on. Restack it for someone who’d argue with you, reply and tell me where you land, or subscribe if you’re new here. I read everything.
In Search Of is where I chase the questions the wellness industry is too sure about.
Appendix: Sources
Bartke, A., et al. GH-deficient Ames dwarf mice live ~50% longer than wild-type littermates, replicated across Snell dwarf and GH-receptor knockout models. Summarized in GeroScience (2025).
Brown-Borg, H.M., et al. “Dwarf mice and the ageing process.” Nature 384, 33 (1996).
Junnila, Bartke, Lasher, et al. “Isolating the direct effects of growth hormone on lifespan and metabolism in mice.” Aging Cell (2024). Confirms the reversal is causal, not just correlational.
BPC-157 mechanism: VEGFR2-mediated angiogenesis, Egr-1/NAB2 regulatory loop, FAK-paxillin signaling. See Journal of Molecular Medicine (2016) and subsequent literature review, Pharmaceuticals (2025).
Jastreboff, A.M., et al. “Retatrutide for Obesity — A Phase 2 Trial.” NEJM 389:514-526 (2023).
Eli Lilly, TRIUMPH-1 Phase 3 topline results, May 21, 2026; TRIUMPH-4 results, December 2025. Full peer-reviewed data still pending.
FDA Pharmacy Compounding Advisory Committee, July 23-24, 2026 votes. Reported by ABC News, TIME, Reuters, STAT News. Advisory only, not equivalent to legalization.
FDA Interim Policy on Compounding (2023 Category 2 placement); HHS announcement, Feb 27, 2026, reviewing 14 restricted peptides.
Lilly FY2025 earnings: Mounjaro/Zepbound combined revenue $36.5B, ~56% of total (reported Feb 2026).